Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

ARNA 4.34 -0.02 (-0.46%)
price chart
Arena Pharmaceuticals Could Have Better Luck In Quarter 2 (ARNA)
New prescription numbers for week ending March 13 have been released by IMS for Belviq (see Table 1), the anti-obesity agent from Arena Pharmaceuticals (NASDAQ:ARNA). The week-to-week improvements in total (TRx) and new (NRx) prescriptions are ...
ARNA Crosses Below Key Moving Average Level
In trading on Tuesday, shares of Arena Pharmaceuticals Inc (Symbol: ARNA) crossed below their 200 day moving average of $4.54, changing hands as low as $4.50 per share.
Fourth quarter updates on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Arena Pharmaceuticals, Inc. Short Interest Disclosure  Stafford Daily
Mid-Day Buzzers � Arena Pharmaceuticals (ARNA), Marvell (MRVL), Himax ...  Techsonian (press release)
Arena Pharmaceuticals (ARNA) Marked As A Dead Cat Bounce Stock
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors.
Price Target Update on Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) should head towards $6.83 per share according to 6 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $5 per share.
Earnings Reaction History: Arena Pharmaceuticals, Inc., 42.9% Follow-Through ...
Over the prior three fiscal years (12 quarters), when shares of ARNA rose in the extended-hours session in reaction to its earnings announcement, history shows that 25.0% of the time (1 event) the stock posted additional gains in the following regular ...
Arena Pharmaceuticals Inc. (ARNA) is Trading Higher on Unusual Volume for ...
Arena Pharmaceuticals Inc. ($ARNA) experienced unusually high volume on Mar. 17, as the stock gained 5.27% to a closing price of $4.99.
Zacks Rating Update on Arena Pharmaceuticals, Inc.
Research firm Zacks has rated Arena Pharmaceuticals (NASDAQ:ARNA) and has ranked it at 4, indicating that for the short term the shares are a sell.
Arena Pharmaceuticals Now Likely To Miss Q1 Estimates (ARNA)
New prescription numbers have been released by IMS for Belviq (see Table 1), the anti-obesity agent from Arena Pharmaceuticals (NASDAQ:ARNA). The 3.3% week-to-week improvement in total prescriptions (TRx) is a slight improvement over the previous ...
Healthcare Stocks in the Spotlight: Arena Pharmaceuticals (ARNA), Genetic ...  Techsonian (press release)
Arena Pharmaceuticals Misses Q4 Expectations
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported financial results Monday for the fourth quarter and full year ended December 31, 2014.
Analyst Rating Update on Arena Pharmaceuticals, Inc.  Stafford Daily
Stock To Watch : Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)  Markets Wired